#ESMO26 | GDFATHER-NEO Phase II trial (n=31) evaluating nivolumab ± visugromab (anti-GDF-15) in MIBC. Adding visugromab nearly quadrupled pCR and ORR, with no safety issue. Promisi

Martin ZapataLaguado· @zapatalaguadomd · X·2026-10-24 17:32· 19 小时前评分70

正文 · 机器翻译

#ESMO26 | GDFATHER-NEO II期试验（n=31），在 MIBC 中评估 nivolumab ± visugromab（抗 GDF-15）。加入 visugromab 后，pCR 和 ORR 几乎增至四倍，且未出现安全问题。膀胱保留前景可期。@SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily

32 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

2081PNCT04949113 NCT04949113 NCT04949113按 Melanoma 对上

Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity

https://esmocongress.esmo.org

4736O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上

Results from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)

https://esmocongress.esmo.org

4757RO按 Rapid oral 1: Genitourinary tumours, renal and urothelial 对上

Final pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)

https://esmocongress.esmo.org

LBA54按 Proffered paper: Melanoma and other skin tumours 对上

Primary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma

https://esmocongress.esmo.org

NCT04884282NCT04884282按 - **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) 对上

- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

https://esmocongress.esmo.org

来源：Martin ZapataLaguado · x.com